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In the original version, the drug ‘metamizole sodium’ was shown twice in table 4, both as the active ingredient itself as 
well as a preparation containing the active ingredient (trade name ‘Novaminesulfone’). In the corrected version, table 
4 shows the order of medications after merging the two entries (i.e. assigning the brand ‘Novaminesulfone’ to the group 
of ‘metamizole sodium’).
In the running text on page 14, the sentence “Therefore, triptans are particularly taken by people with migraine and are 
ranked at place four with 7.3%.” has been corrected accordingly. The correct sentence reads: “Therefore, triptans are 
particularly taken by people with migraine and are ranked at place five with 7.3%.”
The corrected version of the article is available at DOI 10.25646/6990.2
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